In results that is a turning point in a battle, a recent study presented during the European Obesity Conference in 2025 in the Spanish city of Malaga revealed the superiority of “Terzopatid” over its famous rival “Simaglotide” – commercially known as “Ozmbek” and “Wigofi” – in weight reduction among people with obesity without a knife.
The study, which included 751 participants, was randomly distributed to receive one of the two drugs over 72 weeks, showed that the average weight loss in the users of “Terzopatid” amounted to 20.2% of body weight, compared to only 13.7% for “Simiglotide” users; What reflects a relative difference of 47%. The new medicine also excelled in reducing the waist circumference at a rate of 18.4 cm compared to 13 cm, or by more than 42%.
The researchers attribute this remarkable difference to the unique “Terzopatid” mechanism, as it activates two hormonal futures associated with metabolism (GIP and GLP-1) at the same time, while “Simiglotide” is limited to stimulating only one future. This double activation shares, according to experts, in improving heart indicators and metabolism, such as blood pressure, fat, and sugar levels.
It is also noteworthy that 65% of “Terzopatid” users lost at least 15% of their weight, compared to only 40% of “Simiglotide” users. As for the waist circumference, each reduction by 5 cm may reduce the risk of death by between 7 and 9%; What gives these results is very clinical importance.
Although the study was not “generalized” – that is, the patients were aware of the type of treatment they receive – their results were consistent with previous studies underwent a double blindness; What reinforces the credibility of the results.
According to the conference specialists, the study alerts that medicines targeting more than a past path may carry a new and promising key to the treatment of obesity, in light of the increasing demand for effective and safe solutions to weight loss.
